Chest
Selected ReportsOrganizing Pneumonia as a Side Effect of Ipilimumab Treatment of Melanoma
Section snippets
Case Report
A 58-year-old white woman was admitted to our hospital with complaints of cough and dyspnea starting 2 weeks previously. Despite a 7-day course of azithromycin, her cough persisted and she developed worsening shortness of breath. Past medical history was significant for recently diagnosed melanoma of the foot with metastasis to the inguinal lymph nodes, cryptogenic cirrhosis, hypertension, hyperlipidemia with a history of stroke, and a positive anticardiolipin antibody. Home medications
Discussion
The CTLA-4 receptor on T lymphocytes is a negative regulator of lymphocyte activation that binds to B7 on antigen-presenting cells, resulting in an inhibitory signal to the T cell.1 Ipilimumab has a high affinity for CTLA-4, effectively impeding binding to B7, which may potentiate T-cell activation against tumor cells. Ipilimumab has been shown to have a survival benefit in treating metastatic melanoma2 and is also being investigated as potential treatment of hematologic malignancies,3, 4 and
Acknowledgments
Financial/nonfinancial disclosures: The authors have reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
References (21)
- et al.
Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade
Semin Oncol
(2010) - et al.
CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation
Blood
(2009) - et al.
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
Lancet Oncol
(2012) - et al.
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
Lancet Oncol
(2012) - et al.
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications
Semin Oncol
(2010) - et al.
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
Ann Oncol
(2010) - et al.
Increase of activated T-cells in BAL fluid of Japanese patients with bronchiolitis obliterans organizing pneumonia and chronic eosinophilic pneumonia
Chest
(1995) - et al.
Ipilimumab: a novel treatment for metastatic melanoma
Ann Pharmacother
(2011) - et al.
Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma
Clin Cancer Res
(2009) - et al.
Ipilimumab: its potential in non-small cell lung cancer
Ther Adv Med Oncol
(2012)
Cited by (0)
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.